RISK WATCHFintel • 1d ago
Jefferies Downgrades Boston Scientific to Hold from BuyWhy BSX Stock advanced +0.61% Today — RQD Quant Desk Flash
$42.69 +0.61% NYSE • Public Delayed / 60s Snapshot
Boston Scientific Corporation (BSX) carries a Roarable Rating of C+ (Hold) with 66/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
ROARABLE C+ • HOLD / WATCH
Cap $61.87B
INTERACTIVE SCENARIO DECK:
RQD QUANT TACHOMETERHOLD / WATCH • C+
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale
5-PILLAR SNOWFLAKE RADARRw C · Rk B
Each axis scored 0–20
12M PRICE TARGET CONE+3.6% Base Target
WHALE OPTIONS TUG-OF-WAR:54% Call Buyers ($6.0M)
46% PutsMax Pain: $42.00
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why BSX Stock advanced +0.61% Today — RQD Quant Desk Flash
Boston Scientific Corporation (BSX) advanced +0.61% to $42.69 as options desks priced 54% call premium vs. 46% put protection around the $42 max-pain magnet. Solid 69% profit margin (9% return on capital), mixed timing at 22x P/E—hold if owned, no rush to chase.
- ▸Technical Tape: Trading at 5% of its 52-week range ($39.57 – $105.65) with RSI-14 at 38.8 (NEUTRAL RANGE).
- ▸Whale Options Positioning: $6.0M in bullish call flow vs. $5.1M in put flow (Put/Call 0.86x, implied earnings swing ±6.9%).
- ▸Fundamental Anchor: Roarable C+ (Hold) backed by 69% gross margin and $3.7B annual free cash flow.
Live BSX Headlines & Catalysts
CATALYSTYahoo • 1d ago
Intuitive Surgical vs. Boston Scientific: Which Stock Is a Better Buy Now?Intuitive Surgical's surging robotic surgery demand and stronger earnings momentum make it a better buy than Boston Scientific despite its valuation premium.
RISK WATCHBenzinga • 1d ago
TD Cowen Downgrades Boston Scientific to Hold, Lowers Price Target to $46TD Cowen analyst Joshua Jennings downgrades Boston Scientific (NYSE:BSX) from Buy to Hold and lowers the price target from $56 to $46.
CATALYSTYahoo • 1d ago
JNJ's MedTech Segment Disappoints in Q3: Will Growth Rebound in Q4?J&J's MedTech growth slows in Q3 amid international market challenges and Abiomed weakness.
MARKET WIREYahoo • 1d ago
Buy, Sell, or Hold? Today’s Top Upgrades and Downgrades: Boston Scientific, DoorDash, GE Vernova, Honeywell Aerospace, Incyte. Intel, Reddit, Rivian Automotive, and MoreTech giants are rattling pre-market futures on Halloween Eve, and Wall Street analysts are scrambling to reprice everything from chipmakers to delivery apps. Find out which stocks just got upgraded despite the chaos and
MARKET WIREBenzinga • 2d ago
Barclays Maintains Equal-Weight on Boston Scientific, Lowers Price Target to $45Barclays analyst Christopher Pasquale maintains Boston Scientific (NYSE:BSX) with a Equal-Weight and lowers the price target from $48 to $45.
CATALYSTYahoo • 2d ago
New Strong Sell Stocks for October 30thBSX, NBHC and NMRK have been added to the Zacks Rank #5 (Strong Sell) List on October 30th, 2026.
RISK WATCHYahoo • 2d ago
Cyberattack Fallout Could Be A Game Changer For Boston Scientific (BSX)Boston Scientific reported Q3 2026 sales of US$5,138 million and net income of US$582 million, alongside impairment charges and a reduced full year outlook after a prior cyberattack disrupted manufacturing and shipments.
MARKET WIREYahoo • 2d ago
Penumbra, Inc. Reports Third Quarter 2026 Financial ResultsPenumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the third quarter ended September 30, 2026.
MARKET WIREYahoo • 2d ago
Boston Scientific (BSX) Wins FDA Clearances, Starts Elite AF Trial And Expands AI PushBoston Scientific (NYSE: BSX) reported new FDA clearances for urology technologies and an advanced intravascular lithotripsy system. The business enrolled the first patient in the Elite AF clinical trial for its next gen
🔴 SUNDAY NIGHT PREP • 7:00 PM ETHosted Live by Perry Belcher & Guest Trading Systems Desk
Today's Top 3 RQD Strong Buys & Whale Accumulation Setups (Live BSX Tape Review)
- ✓Live breakdown of today’s highest-scoring RQD Green-Light breakouts
- ✓1 urgent Red-Light accounting trap to cut from your watchlist immediately
- ✓Bring any ticker to live Q&A—we run it through the 5-Pillar RQD Radar on screen
RQD INSIDER CLUB UPGRADE$49/YEAR
Want Plain-English AI Custom Indicators, Daily Pro Trader Video Clips & SMS Crash Alerts?
BSX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -27.13%▼ DESCENDING CHANNEL
2026-10-30O $42.95H $43.29L $41.73C $41.98VOL 22.47M
RES: $45.46SUP: $39.51SMA50: $44.79SMA200: $56.52
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
BSX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
15.7%/yr Implied 5Y Growth
vs. +19.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on BSX today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for BSX. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BSX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
BSX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is BSX stock moving today?
Why BSX Stock advanced +0.61% Today — RQD Quant Desk Flash. Solid 69% profit margin (9% return on capital), mixed timing at 22x P/E—hold if owned, no rush to chase.